RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

The RAPS store will be under maintenance Saturday, 13 June between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > In Focus: Labeling

In Focus: Labeling

Posted 01 April 2008 | By

Labeling has long been the document that conveys years of research and testing knowledge about a product's safe and effective use to healthcare providers. Labeling has also formed the foundation for promotion and advertising claims about a product. Most labeling formats and guidelines for the US and the EU were designed many years ago and updated only recently. Updates, worldwide, are intended to simplify the labeling document, making it more user-friendly. In addition, recent regulations are designed to ensure that labeling fully informs physicians and patients about a product's correct use. In the US, these regulations require structured product labeling (SPL) format, requiring certain drugs to include a patient package insert in a specific format utilizing consumer-friendly language. In the EU, package leaflet readability and understanding must be formally assessed prior to product approval. This issue of Regulatory Focus provides a closer look at the EU's requirements and the processes professionals should employ in user testing and working with the regulatory bodies.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.